Compare · GRPH vs KRBP

GRPH vs KRBP

Side-by-side comparison of Graphite Bio Inc. (GRPH) and Kiromic BioPharma Inc. (KRBP): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both GRPH and KRBP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
  • GRPH has more recent analyst coverage (16 ratings vs 0 for KRBP).
MetricGRPHKRBP
Company
Graphite Bio Inc.
Kiromic BioPharma Inc.
Price
-
-
Market cap
-
-
1M return
-
-
1Y return
-
-
Industry
Medicinal Chemicals and Botanical Products
Medicinal Chemicals and Botanical Products
Exchange
NASDAQ
NASDAQ
IPO
2021
2020
News (4w)
0
0
Recent ratings
16
0
GRPH

Graphite Bio Inc.

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

KRBP

Kiromic BioPharma Inc.

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Latest GRPH

Latest KRBP